$Refractoriness and retreatment in the era of lenalidomide and mABs in the frontline myeloma setting ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )$

18 Oct 2021

Melflufen and dexamethasone vs pomalidomide and dexamethasone in relapsed refrac...

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway

$Melflufen and dexamethasone vs pomalidomide and dexamethasone in relapsed refractory multiple myeloma ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )$

21 Sep 2021

New MM patients with high levels of circulating tumour cells distinguished by in...

Dr Cathelijne Fokkema - Erasmus MC Cancer Institute, Rotterdam, Netherlands

21 Sep 2021

Novel therapies in multiple myeloma

Dr Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA

20 Sep 2021

Disparities in myeloma: Closing the gap

Prof Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA

20 Sep 2021

CARTITUDE-2: Ciltacabtagene autoleucel in patients with progressive multiple mye...

Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA

19 Sep 2021

Impact of cytogenetic abnormalities on treatment outcomes in patients with AL am...

Dr Shaji Kumar - Mayo Clinic, Rochester, USA

19 Sep 2021

B-cell maturation antigen targeted CD3-engaging bispecific molecule for relapsed...

Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville, U...

$B-cell maturation antigen targeted CD3-engaging bispecific molecule for relapsed or refractory multiple myeloma ( Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville, USA )$

18 Sep 2021

Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethaso...

Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain